Supply Requirement Update- Fondaparinux Injection
Post date: Mar 29, 2017 4:49:47 AM
20th March 2017 (Circular No. SP PPUM: 109 /2017):
Fondaparinux Injection, which was restricted for supply to Government Servants, Government Pensioners and their dependants, can now be supplied to any Inpatient requiring the medication.
However, the indication for supply has also been tightened. Where previously, Fondaparinux Injection can be used for prevention, it can now only be used to treat:
Acute Coronary Syndrome
Pulmonary Embolism
Deep Vein Thrombosis
for a maximum duration of FIVE (5) DAYS, where before this it was supplied for seven (7) days.
Patients who require the medication beyond five (5) days will need to purchase the additional supply of Fondaparinux Injection from PharmUMMC.
For certain conditions, the concurrent use of Warfarin will ensure that the need for Fondaparinux Injection does not extend beyond five (5) days.
Patients being treated with Fondaparinux Injection for indications other than those mentioned above will also need to purchase their supply from PharmUMMC.
This current supply criteria was endorsed by UMMC's Drugs and Therapeutics Sub-Committee on 13th March 2017.